#Sustainability #China #Shanghai #WuXi Biologics #DJSI

WuXi Biologics Ranks Top in Dow Jones Sustainability Indices 2024

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a significant achievement. For the second consecutive year, the company has been listed among the top performers in the 2024 Dow Jones Sustainability Indices (DJSI). This recognition underscores its continuous commitment to sustainability and responsible business practices.

The Dow Jones Sustainability Indices have long been recognized as a vital benchmark for investors who prioritize sustainable practices. Launched in 1999, the DJSI offers insight into companies that not only pursue profitability but also play a proactive role in addressing environmental, social, and governance (ESG) challenges. Among the DJSI rankings, the DJSI World represents the top 10% of the largest 2,500 companies in the SP Global Broad Market Index, based on their ESG performances.

Dr. Chris Chen, the CEO of WuXi Biologics, expressed pride in the company's inclusion on the DJSI. He stated, “We are honored to be included in the DJSI list for the second consecutive year. It is a reflection of and recognition for our continuous commitment to enhancing sustainability capabilities.” He emphasized the company's dedication to innovative practices that not only meet client needs but also contribute positively to global sustainability goals.

WuXi Biologics has made substantial strides in recent years in promoting sustainable development. The company was featured in the UNGC 20 Case Examples of Sustainable Development, which highlights global leaders in this field. Additionally, WuXi Biologics has received numerous accolades, including an AAA rating from MSCI ESG Ratings for two consecutive years, recognition from EcoVadis with a Platinum Medal, and being rated highly by Sustainalytics.

In terms of climate action, WuXi Biologics has been recognized on the CDP Water Security 'A List' and achieved an 'A-' score for CDP Climate Change. The company is also a constituent of the FTSE4Good Index Series and has made it onto the Hang Seng ESG 50 Index. These honors reflect its relentless pursuit of sustainable business practices throughout its operations.

WuXi Biologics, with stock code 2269.HK, operates on a global scale, providing end-to-end solutions that empower partners to discover, develop, and manufacture biologics for patients worldwide. The company boasts a workforce of over 12,000 skilled employees across multiple countries, including China, the United States, Ireland, Germany, and Singapore. With a robust portfolio of 742 integrated client projects, WuXi Biologics is dedicated to utilizing cutting-edge technology to deliver cost-effective biologics solutions.

The company strongly integrates Environmental, Social, and Governance (ESG) responsibilities into its core ethos and business strategies. WuXi Biologics employs next-generation biomanufacturing technologies powered by clean energy. To enhance its sustainability commitments, an ESG committee led by the CEO manages the comprehensive ESG strategies across the organization.

As WuXi Biologics looks ahead, it is determined to uphold its leadership role in ESG initiatives within the CRDMO sector. The company aims to advance its innovative and sustainable approaches, working closely with stakeholders across the supply chain to promote responsible practices that benefit both business and society as a whole.

For more information about WuXi Biologics and its commitment to sustainability, visit WuXi Biologics.